AGI.do

Products

What will AGI do for Avanafil?

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular structure C23H26CLN7O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, DR5S136IVO chemically known as 5-pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2s)-2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-, but more commonly known as avanafil, which bears U.S. NIH Compound Identifier 9869929. European Medicines Agency schedules Avanafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34916. The term AVANAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 19, no. 3, 2005, list 54).

How AGI delivers it

Four ways AGI delivers for Avanafil

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Avanafil, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Avanafil, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Avanafil connects

measured by

  • Active Ingredient Potencymodel
  • Compound Puritymodel
  • Particle Sizemodel
  • Particle Size Distributionmodel
  • Residual Solventmodel

Go deeper

Explore Avanafil

Read the deeper take on agi.asView as markdown